- BELLUS Health Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for chronic cough and other hypersensitization disorders. - Their lead drug candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for chronic cough. It has the potential for best-in-class efficacy and tolerability based on preclinical and clinical data. - BELLUS has a balanced pipeline that includes partnered programs in sarcoidosis, Alzheimer's disease, and Fragile X syndrome in addition to their wholly-owned chronic cough program.